The $35K Biocomputer Is Here. Now What?

Cortical Labs just proved that you can build a working computer out of living human brain cells. Now the hard part begins: figuring out what to actually do with it.

The CL1, which started shipping in summer 2025, isn't a gaming rig. It's 800,000 lab-grown human neurons cultivated on a silicon chip, kept alive by an internal life-support system, and connected to your code via Python. For $35,000 per unit—or $20,000 if you buy 30 at a time—you get what Cortical Labs calls "synthetic biological intelligence." It's neuromorphic computing taken to its logical extreme: not emulating neurons, but using the real thing.

The demo was perfect. A biocomputer playing Doom. The internet ate it up. But that announcement in March 2026 was actually the punchline to a much longer setup that started years ago.

From Pong to Doom: Proof Points

Back in 2021, Cortical Labs showed off DishBrain, an earlier version of this technology that learned to play Pong. That took 18 months. The jump from Pong to Doom sounds trivial—it's just a harder game—but it's not. Doom requires real-time visual processing and tactical decision-making. A developer named Sean Cole, who had no background in biological computing, figured out how to convert Doom's visual input into electrical stimulation patterns the neurons could understand. He did it in a week.

That's the moment that matters. Not the game itself, but the fact that someone without specialized neuroscience training could program a biocomputer. The CL1's Python interface democratizes something that was previously locked behind PhDs and specialized lab equipment.

Why This Actually Matters

The hype is real, but it's not about gaming. Cortical Labs is positioning the CL1 for three serious use cases: drug discovery, clinical testing, and robotics. And they're not wrong.

Current drug testing relies on either silicon-based simulations (which are increasingly accurate but still models) or animal testing (which is ethically fraught and biologically imperfect). A biocomputer with real human neurons offers something in between: actual human biology responding to compounds in real time, with none of the ethical baggage of animal testing.

The IEEE Spectrum piece on the CL1 quoted Karl Friston, a theoretical neuroscientist at UCL, calling it "an enabling technology that allows scientists to perform experiments on a little synthetic brain." That's the actual value proposition. Not a replacement for silicon chips—your laptop isn't getting a biological CPU—but a tool for understanding how neural systems work and respond to stimuli.

For drug discovery, that's huge. Pharmaceutical companies spend billions testing compounds on animal models that don't perfectly predict human outcomes. A biocomputer with human neurons could accelerate that process and improve accuracy. The addressable market there is enormous.

The Energy Angle Nobody's Talking About

Here's the thing that gets buried in the Doom demo hype: the CL1 uses almost no power. It's designed to keep neurons alive for up to six months on minimal inputs. Compare that to training a modern AI model, which can consume megawatts of electricity and require specialized cooling infrastructure.

Biological systems are fundamentally more energy-efficient than silicon for certain tasks. That's not philosophy—it's physics. Neurons have been solving complex problems with minimal energy expenditure for 600 million years. A biocomputer that could replicate even a fraction of that efficiency while handling real-time learning would change the economics of computing.

The catch? We don't really know yet what tasks are actually suited for biological computing versus silicon. That's what the next five years will determine.

The Elephant in the Room

Cortical Labs is careful about this. They've got bioethics oversight built into their commercialization roadmap. But the question lingers: what happens if you scale this up? What if you're not running 800,000 neurons, but 800 million? At what point does a synthetic neural network become... something we need to have a different conversation about?

Cortical Labs isn't there yet. They're talking about a "Minimal Viable Brain"—a controlled neural system capable of complex information processing. The company also plans to network multiple CL1 units into larger systems. That's still years away, and it's still far from anything resembling consciousness or sentience. But it's worth thinking about now, before it becomes a technical problem instead of a theoretical one.

What Happens Next

The first batch of CL1 units is in labs now. Researchers at institutions that can afford $35K (or have access to Cortical's cloud-based "Wetware-as-a-Service" at $300 per week) are running experiments. We'll see results in drug discovery and neuroscience research within 12-18 months. That will tell us whether the hype is justified.

The real inflection point comes when the price drops and the capabilities expand. Right now, the CL1 is a research tool for specialists. If it becomes a commodity—if biocomputers become as accessible as GPU instances on AWS—then we're talking about a genuine shift in how computation happens.

Cortical Labs is building the hardware and the interface. The rest is up to the scientific community to figure out what this thing is actually good for. Playing Doom was fun. Now let's see what they can really do with it.

The Bottom Line

Cortical Labs has shipped the first commercially viable biocomputer. It works. It learns. It plays video games. But the company's real achievement wasn't proving that biological computing is possible—we've known that since neurons exist. It was making it accessible. Programmable. Scalable.

That's when the interesting part starts.